Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.45 |
| ▸ | PRKCA | P17252 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | PDCD4 | Q53EL6 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833125 | 1.00 | PLA2G2C (0.48) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL30722293 | 0.94 | TSHR (0.52) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL16265047 | 0.92 | TSHR (0.44) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL11041362 | 0.90 | USP2 (0.49) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL11124230 | 0.87 | USP2 (0.49) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL11121672 | 0.87 | USP2 (0.49) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL8138708 | 0.86 | PLA2G2C (0.39) | PLA2G2CGLS2PRKCATSHRUSP2 | |
| SCHEMBL4016772 | 0.86 | USP2 (0.54) | PLA2G2CGLS2TSHRUSP2ALDH1A1 | |
| SCHEMBL29270065 | 0.86 | TSHR (0.45) | PLA2G2CGLS2TSHRUSP2ALDH1A1 | |
| SCHEMBL12060199 | 0.86 | PRKCA (0.53) | GLS2PRKCAMAPTFAAHPDCD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507854-B2 | Impurity reduction in Olefin metathesis reactions | MATERIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20050203324-A1 | Impurity reduction in Olefin metathesis reactions | MATERIA, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203324-A1 | Impurity reduction in Olefin metathesis reactions | CYP51A1, COASY, ECI1 | PLA2G2C 4097/4885GLS2 4215/4885PRKCA 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.